SERD Therapeutics Market
完整報告名稱與涵蓋範圍
SERD Therapeutics Market Size, Share & Trends Analysis Report By Products (Faslodex, Elacestrant, Camizestrant (AZD9833), Giredestrant (GDC-9545), Imlunestrant (LY3484356), Other Pipeline Products), By Route of Administration, By Indication, Region, And Segment Forecasts, 2025-2034
報告摘要
The SERD Therapeutics Market on a global scale was estimated at USD 1339.0 Mn in 2024 and is projected to attain USD 2108.7 Mn by 2034, with a projected CAGR of 4.8% between 2025 and 2034.
The SERD Therapeutics sector involves a type of drug which downregulates the estrogen receptor. This domain has witnessed considerable transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is fueled by growing healthcare spending, technological evolution, and the growing focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and growing investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global SERD Therapeutics Market Snapshot
Chapter 4. Global SERD Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter's Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Key Trends in the Market
4.8. COVID 19 Impact Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Faslodex
5.2.2. Elacestrant
5.2.3. Camizestrant (AZD9833)
5.2.4. Giredestrant (GDC-9545)
5.2.5. Imlunestrant (LY3484356)
Other Pipeline Products
Chapter 6. SERD Therapeutics Market Segmentation 2: By Route of Administration Estimates & Trend Analysis
6.1. By Route of Administration Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:
6.2.1. Intramuscular
6.2.2. Oral
6.2.3. Infusion
6.2.4. Subcutaneous
6.2.5. Parenteral
6.2.6. Other
Chapter 6. SERD Therapeutics Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. By Indication Analysis & Market Share, 2024 & 2034
7.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indication:
7.2.1. ER-positive
7.2.2. HER2-negative
7.2.3. ESR1-mutated advanced or metastatic breast cancer.
7.2.4. Other
Chapter 8. SERD Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
8.1.2. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
8.1.3. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
8.1.4. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.2.2. Europe SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.2.3. Europe SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.2.4. Europe SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.8. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.3.2. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.3.3. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.3.4. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.4.2. Latin America SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.4.3. Latin America SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.4.4. Latin America SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.5.2. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.5.3. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.5.4. MEA revenue SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global SERD Therapeutics Market Snapshot
Chapter 4. Global SERD Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter's Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Key Trends in the Market
4.8. COVID 19 Impact Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Faslodex
5.2.2. Elacestrant
5.2.3. Camizestrant (AZD9833)
5.2.4. Giredestrant (GDC-9545)
5.2.5. Imlunestrant (LY3484356)
5.2.6. Other Pipeline Products
Chapter 6. SERD Therapeutics Market Segmentation 2: By Route of Administration Estimates & Trend Analysis
6.1. By Route of Administration Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:
6.2.1. Intramuscular
6.2.2. Oral
6.2.3. Infusion
6.2.4. Subcutaneous
6.2.5. Parenteral
6.2.6. Other
Chapter 7. SERD Therapeutics Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. By Indication Analysis & Market Share, 2024 & 2034
7.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indication:
7.2.1. ER-positive
7.2.2. HER2-negative
7.2.3. ESR1-mutated advanced or metastatic breast cancer.
7.2.4. Other
Chapter 8. SERD Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
8.1.2. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
8.1.3. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
8.1.4. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.2.2. Europe SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.2.3. Europe SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.2.4. Europe SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.8. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.3.2. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.3.3. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.3.4. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.4.2. Latin America SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.4.3. Latin America SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.4.4. Latin America SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.5.2. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.5.3. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.5.4. MEA revenue SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Amneal Pharmaceuticals Inc
8.2.2. AstraZeneca, Plc.
8.2.3. Dr. Reddy's Laboratories
8.2.4. Eli Lilly and Company
8.2.5. G1 Therapeutics, Inc.
8.2.6. Glenmark Pharmaceuticals
8.2.7. HBT Labs, Inc
8.2.8. Hoffmann-La Roche AG
8.2.9. InventisBio
8.2.10. Novartis AG
8.2.11. Radius Health
8.2.12. Sanofi S.A.
8.2.13. Teva Pharmaceutical Industries Ltd.
8.2.14. Zenopharm LLC.
8.2.15. Zentalis Pharmaceuticals
8.2.16. Genentech
8.2.17. Olema Pharmaceuticals
8.2.18. Aragon Pharmaceuticals
8.2.19. Sun Pharma Advanced Research Company
8.2.20. Shandong Luoxin Pharmaceutical
8.2.21. Zeno Alpha
8.2.22. Atossa Therapeutics
8.2.23. Evestra
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們